Companies in the News

BlackThorn Therapeutics To Receive Up to $8 Million in NIH Blueprint Neurotherapeutics Network Fundi

South San Francisco, Calif. – June 20, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, today announced it has received a grant from the National Institute of Neurological Disorders and Stroke (NINDS) of the National Institutes of Health (NIH). The grant is funded as part of the Blueprint Neurotherapeutics Network (BPN) of the NIH Blueprint for Neuroscience Research, a collaboration of NIH Institutes and Centers that supports research on the nervous system with the goal of developing new neurotherapeutic drugs. This award is worth up to $8 million to support BlackThorn’s development of kap

eFFECTOR Therapeutics to Collaborate with Pfizer and Merck KGaA, Darmstadt, Germany to Evaluate a No

SAN DIEGO, June 20, 2017 /PRNewswire/ -- eFFECTOR Therapeutics announced today it has entered into a clinical collaboration and supply agreement with Pfizer and Merck KGaA, Darmstadt, Germany, to evaluate the combination of two immuno-oncology agents in patients with microsatellite stable colorectal cancer (CRC). The companies plan to initiate a Phase 2 open-label, randomized, non-comparative study to evaluate the safety, tolerability and efficacy of eFFECTOR's investigational small molecule MNK1/2 inhibitor, eFT508, in combination with avelumab* in microsatellite stable relapsed or refractory CRC patients. Avelumab is currently under clinical evaluation across a broad range of tumor types b

BlackThorn Therapeutics Announces Innovative Clinical Collaboration Agreement with Mindstrong Health

BLACKTHORN’S BTRX-246040 NOCICEPTIN PROGRAM IS FIRST MOLECULE AND CLINICAL PROGRAM TO INCORPORATE MINDSTRONG HEALTH’S PATENTED TECHNOLOGY PLATFORM South San Francisco, Calif. – June 7, 2017 – BlackThorn Therapeutics, a clinical-stage biopharmaceutical company discovering and developing targeted treatments for neurobehavioral disorders, today announced that it has entered into a clinical collaboration agreement with Mindstrong Health, a private biotechnology company working to transform the diagnosis and management of neurobehavioral disorders. Under the terms of the agreement, BlackThorn will use Mindstrong Health’s patented and validated technology to passively collect digital behavioral bi